Oncotarget

Meta-Analysis:

Clinicopathological, prognostic and predictive value of CD166 expression in colorectal cancer: a meta-analysis

Susu Han, Wei Yang, Shaoqi Zong, Hongjia Li, Shanshan Liu, Wen Li, Qi Shi _ and Fenggang Hou

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:64373-64384. https://doi.org/10.18632/oncotarget.17442

Metrics: PDF 1488 views  |   HTML 2917 views  |   ?  


Abstract

Susu Han1,*, Wei Yang1,*, Shaoqi Zong1, Hongjia Li1, Shanshan Liu1, Wen Li1, Qi Shi1 and Fenggang Hou1

1 Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai, People’s Republic of China

* Co-first authors

Correspondence to:

Fenggang Hou, email:

Qi Shi, email:

Keywords: CD166, expression, CRC, survival, clinical features

Received: December 28, 2016 Accepted: March 13, 2017 Published: April 26, 2017

Abstract

CD166 has been identified as an important cancer stem cell (CSC) marker in colorectal cancer (CRC). The purpose of our study was to investigate the relationship between CD166 expression and clinical features and to examine the role of CD166 expression on the survival of patients with CRC. A total of 15 studies with 3,332 cases were identified in this meta-analysis. The pooled OR indicated that CD166 expression was significantly higher in CRC than in colonic adenomas or normal colonic mucosa (OR = 3.48, P = 0.002 and OR = 55.13, P = 0.017, respectively). CD166 expression was found to be negatively correlated with vascular invasion (OR = 0.75, P = 0.017), but it was not associated with gender, tumor location, lymph node status, distant metastasis, clinical stage, T classification or tumor differentiation. Meanwhile, CD166 expression was not associated with the prognosis of overall survival (OS) (HR = 1.20, 95% CI = 0.45-3.22, P = 0.72) in multivariate regression analysis. One study reported that CD166 expression may be a predictor of survival in stage II CRC patients using multivariate logistic regression analysis (OS: OR = 9.97, P = 0.035; disease-specific survival: OR = 29.02, P = 0.011). Our findings suggest that CD166 expression may be correlated with CRC carcinogenesis and a decreased risk of vascular invasion, and it may become a predictive biomarker of survival for stage II CRC patients, but additional studies with large sample sizes are essential to validate the prognostic and predictive values of CD166 expression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17442